Status:
COMPLETED
Implication of Metabolic and Genomic Modifications in Elderly Subjects
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Insulin Sensitivity
Aging
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
An increase of longevity and of the number of men and women older than 60 years old is observed in most industrialized countries. Aging is a complex, multifactorial and continuous process involving ph...
Eligibility Criteria
Inclusion
- Volunteers from the cohort aging SUVIMAX 2
- Men and Women
- over 60 years
- BMI between 18 and 35 kg/m2 (including terminals)
- Normal medical check up
- Blood pressure \< 140/90 mmHg
- Normal glycemia, lipid profile
- sedentary or moderate physical activity (maximum 4 hours per week)
Exclusion
- Biological results or anormal chek-up
- medical or surgical history not compatible with study
- severe digestive, cardiovascular, renal, liver or tumor disorders history in the 5 last years
- infectious or inflammatory disease within 2 months
- surgical history within 3 months
- bood donation within 2 months
- coagulation disease, anticoagulant or antiplatelet agents (aspirin ...) treatment
- xylocaïn allergy
- claustrophobia
- Drug that could affect insulin sensitivity (beta blockers, lipid lowering, oral antidiabetics, insulin, , steroids)
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00951392
Start Date
May 1 2009
End Date
November 1 2009
Last Update
May 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de recherche en nutrition humaine Rhône-Alpes
Pierre-Bénite, France, 69495